攝護腺癌荷爾蒙治療與甲狀腺疾病之相關性分析

柳瑞明¹, 莊恆彰¹, 吳俊德² 許仁駿³

¹衛生福利部桃園醫院 泌尿科;²長庚醫療財團法人基隆長庚紀念醫院 泌尿科; ³佛教慈濟醫療財團法人花蓮慈濟醫院 癌症研究中心

The association between androgen deprivation therapy and the risk of thyroid diseases

 Jui-Ming Liu¹, Heng-Chang Chuang¹, Chun-Te Wu² Ren-Jun Hsu ³

1Division of Urology, Department of Surgery Taoyuan General Hospital, Ministry of Health and Welfare

2 Department of Urology, Chang Gung Memorial Hospital, Keelung, Taiwan

3 Cancer Medicine Center of Buddhist Hualien Tzu Chi Hospital, Tzu Chi University, Hualien, Taiwan

Background:

Androgen deprivation therapy (ADT) is widely used in advanced prostate cancer. To test the impact of ADT on the risk of thyroid diseases.

Methods:

We used data from the National Health Insurance Research Database of Taiwan between 1997 and 2013. There were 6200 ADT patients comprised the study group with 6200 matched non-ADT controls by propensity-score matched analysis. The demographic characteristics and comorbidities were used t test. Cox proportional hazards regression was used to calculate the hazard ratios (HR) for the risk of thyroid diseases.

Results:

A number of 481 patients with newly diagnosed thyroid diseases were identified. Of those patients, 165 patients were ADT users and 316 were non-ADT users. Compared with non-ADT patients, ADT patients had a lower risk of subsequent thyroid diseases with adjusted HR of 0.79 (95% confidence interval (CI) 0.65-0.95).

Conclusions:

ADT may decrease risk of thyroid diseases in patients with prostate cancer. Further studies are warranted to have fully investigation.